The manufacturer of tripotassium dicitratobismuthate (De-noltab®) has written to healthcare professionals advising that the product will be discontinued with effect from the end of December 2015.
No reason for the decision to discontinue this product is provided in the letter. It is recommended that appropriate alternatives are discussed with any patient who is currently taking this medication as a long term treatment.
Action: Clinicians should be aware of this product being discontinued. It may be prudent to run clinical system searches to identify any patients who are currently prescribed this product to allow a review and an alternative to be arranged.
|« NICE Guidance - May 2015||SMC Update - June 2015 »|